Bill Oxford The market has seen a huge sector rotation recently out of Big Tech and Magnificent Seven stocks into the Dow components, and small and mid-cap stocks. The SPDR® S&P Biotech ETF (XBI) has been the beneficiary of this move. Over the last month, this small/mid-cap biotech ETF has spurted ahead by some 10% while money has come out of the likes of Alphabet Inc. (GOOG), Nvidia Corporation (NVDA) and Microsoft (MSFT). Seeking Alpha If the rally in small and mid-cap biotech equities continues, here ...

Amgen (AMGN) ended the recent trading session at $334.85, demonstrating a +0.16% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 1.11% for the day. At the same time, the Dow added 1.64%, and the tech-heavy Nasdaq gained 1.03%.Prior to today's trading, shares of the world's largest biotech drugmaker had gained 6.57% over the past month. This has outpaced the Medical sector's loss of 0.54% and the S&P 500's loss of 1.16% in that time.Market partici ...

Investors have been on a roller coaster ride for the past four years. One of the longest bull markets in history was brought to a screeching halt by the global pandemic. The S&P 500 lost over one-third of its value in a matter of a few weeks.Yet immediately afterward, the popular benchmark index rocketed higher, more than doubling in value over the next 21 months. It then lost a quarter of its value again before turning north once more and running 50% higher. You’re not alone if you’ve experienced vertigo d ...

Biotech stocks to buy can be an interesting sector for investors. They can provide massive gains following positive news regarding clinical trials or FDA approvals. However, they may also cause large share price drops following bad news or missed expectations surrounding a company’s treatments.In my opinion, when investing in the biotech industry, it’s best to steer clear of smaller companies that are more susceptible to wild swings in their share price. It is much better to stick with larger companies that ...

Amgen offers a packed pipeline and healthy dividend distributions.Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (AMGN 1.77%) is evidently unafraid to reward its loyal shareholders with quarterly cash payments.Just as importantly, Amgen is a recent revenue grower with a diversified pipeline of current and proposed products. So, here's the skinny on how much investors might expect from Amgen's upcoming dividend distributions.How much does Amgen pay in divi ...

The latest trading session saw Amgen (AMGN) ending at $330.83, denoting a +1.77% adjustment from its last day's close. This move outpaced the S&P 500's daily gain of 0.55%. At the same time, the Dow added 0.62%, and the tech-heavy Nasdaq gained 0.63%.The the stock of world's largest biotech drugmaker has risen by 8.91% in the past month, leading the Medical sector's gain of 0.19% and the S&P 500's gain of 4.28%.Analysts and investors alike will be keeping a close eye on the performance of Amgen in its upcom ...

With technology-driven growth stocks propelling the S&P 500 to new heights, dividend stocks have often found themselves playing catch-up.Yet, even in this market environment, some dividend-paying companies have managed not only to keep pace, but also beat the index by a significant margin.Specifically, while the S&P 500 has registered returns of about 27% over the past year, the following three dividend stocks have delivered annual total returns exceeding 30%.More importantly, these three stocks maintain eq ...

This company's payouts look safe.If there is one thing income investors like more than regular dividend payouts, it's regular and growing dividend payouts. Not every corporation can offer that, of course. Some will eventually suspend their dividend programs or, at the very least, decrease their payouts.Fortunately, there are stocks on the market that look committed to returning capital to their shareholders by way of consistent dividend increases. That's what income seekers are after. Let's consider one exc ...

Amgen's market-beating ways are unlikely to evaporate any time soon.Few stocks consistently outperform the vaunted S&P 500 index due to its inherent advantages in diversification and stability. This benchmark index draws its strength from a broad portfolio of America's top companies, allowing it to weather individual sector downturns and capitalize on various market trends simultaneously.Individual stocks, in contrast, are subject to company-specific risks and industry cycles. Even well-managed companies ca ...

PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role. A report from Future Market Insights projects that the global pancreatic cancer mark ...